Dr. Benjamin T. Johnson, MD
CEO
Osmosis, LLC
30746 Bryant Dr, Unit 410
Evergreen , CO 80439
United States
drben@osmosisbeauty.comFEI 3006317401Issued Aug 23, 2023Division of Human and Animal Food Operations East IV
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3006317401.
Violations14
Issue DateAug 23, 2023
Product TypeDrugs
StatusOpen
Letter Details
Firm
Osmosis, LLC
Location
Dr. Benjamin T. Johnson, MD
CEO
Osmosis, LLC
30746 Bryant Dr, Unit 410
Evergreen , CO 80439
United States
drben@osmosisbeauty.com
FEI Number
3006317401
Country
United States
Issue Date
August 23, 2023
Issuing Office
Division of Human and Animal Food Operations East IV
Product Type
Drugs
Status
Open
Summary
Osmosis, LLC was cited for marketing three unapproved drug products—Osmosis Skin Perfection Elixir, Sugar Detox Elixir, and Elevate—in violation of the Federal Food, Drug, and Cosmetic Act. The products made disease claims on their labels and website, including statements that they "detoxify eczema, psoriasis, and inflamed skin" and "balance digestive causes of rosacea," which caused them to be regulated as drugs rather than cosmetics. Because these products lacked FDA approval as new drugs and were misbranded without appropriate drug labeling, their introduction into interstate commerce violated federal law. The violations were identified during an FDA inspection of the company's Colorado manufacturing facility in January 2023 and confirmed through subsequent review of product labels and the company's website in June 2023.